SHC earnings

Q1 2026 net revenues increased 10.0%, or 6.5% on a constant currency basis, compared to Q1 2025Q1 2026 net income of $27 million or $0.09 per diluted share, compared to a net loss of $13 million or $0.05 per diluted share in Q1 2025Q1 2026 Adjusted EBITDA(1) increased 10.5%, or 6.9% on a constant currency basisQ1 2026 Adjusted EPS(1) of $0.18, an increase of 29% per diluted shareCompany reaffirms full-year 2026 outlook of 5.0% - 6.5% net revenues growth and 5.5% - 7.0% Adjusted EBITDA growth, both on a constant currency basisCompany announced planned CEO transition in a separate release today CLEVELAND, May 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Compan

CLEVELAND, April 21, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the first-quarter ended March 31, 2026 before the market opens on Tuesday, May 5, 2026. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's operating and financial results. A live webcast of the conference call and accompanying materials can be accessed via the Investor Relations section of the Company's website at Presentation & Event

2025 net revenues increased 5.7% to $1.164 billion, compared to 2024, or 5.2% on a constant currency basis2025 net income increased to $78 million or $0.27 per diluted share, compared to net income of $44 million, or $0.16 per diluted share, in 20242025 Adjusted EBITDA(1) increased 8.2% to $594 million, compared to 2024, or 7.8% on a constant currency basis2025 Adjusted EPS(1) of $0.86, an increase of $0.16 per diluted share, compared to 2024Full-year 2026 outlook: net revenues growth of 5.0% to 6.5% and Adjusted EBITDA growth of 5.5% to 7.0%, on a constant currency basis CLEVELAND, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC),

CLEVELAND, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2025 before the market opens on Tuesday, February 24, 2026. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. A live webcast of the conference call and accompanying materials can be accessed via the Investor Relations section of the Company's websit

Q3 2025 net revenues increased 9.1% to $311 million, or 8.0% on a constant currency basis(1), compared to Q3 2024Q3 2025 net income of $48 million, or $0.17 per diluted share, compared to net income of $17 million or $0.06 per diluted share in Q3 2024Q3 2025 Adjusted EBITDA(1) increased 12.2% to $164 million, or 11.2% on a constant currency basis, compared to Q3 2024Q3 2025 Adjusted EPS(1) of $0.26, an increase of $0.09 per diluted share, compared to Adjusted EPS of $0.17 in Q3 2024Raising 2025 Adjusted EBITDA growth range to 6.75% - 7.75% and reaffirming net revenues outlook range of 4.5% - 6.0%, on a constant currency basis CLEVELAND, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sotera Health Comp

CLEVELAND, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the third-quarter ended September 30, 2025 before the market opens on Tuesday, November 4, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations. A

Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis(1), compared to Q2 2024Q2 2025 net income of $8 million or $0.03 per diluted share, compared to net income of $9 million or $0.03 per diluted share in Q2 2024Q2 2025 Adjusted EBITDA(1) increased 9.8% to $151 million, or 9.5% on a constant currency basis, compared to Q2 2024Q2 2025 Adjusted EPS(1) of $0.20, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.19 in Q2 2024Raising both full-year 2025 net revenues outlook to 4.5% - 6.0% and Adjusted EBITDA outlook to 6.0% - 7.5%, on a constant currency basis CLEVELAND, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera He

CLEVELAND, July 28, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the second-quarter ended June 30, 2025 before the market opens on Friday, August 8, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations. A live

Q1 2025 net revenues increased 2.6% to $255 million, compared to Q1 2024, or 4.4% on a constant currency basisQ1 2025 net loss of $13 million or $0.05 per diluted share, compared to net income of $6 million or $0.02 per diluted share in Q1 2024Q1 2025 Adjusted EBITDA(1) increased 8.8% to $122 million, compared to Q1 2024, or 11.2% on a constant currency basisQ1 2025 Adjusted EPS(1) of $0.14, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.13 in Q1 2024Company reaffirms full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("

CLEVELAND, April 17, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the first-quarter ended March 31, 2025 before the market opens on Thursday, May 1, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations.

2024 net revenues increased 4.9% to $1.10 billion, compared to 2023; or 5.4% on a constant currency basis2024 net income of $44 million or $0.16 per diluted share, compared to 20232024 Adjusted EBITDA(1) increased 3.9% to $549 million, compared to 2023; or 4.6% on a constant currency basis2024 Adjusted EPS(1) of $0.70, a decrease of $0.02 per diluted share, compared to 2023Full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization so

CLEVELAND, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2024 before the market opens on Thursday, February 27, 2025. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from

Q3 2024 net revenues of $285 million increased 8.5%, compared to Q3 2023Q3 2024 net income of $17 million or $0.06 per diluted share, compared to net loss of $14 million or $0.05 per diluted share in Q3 2023 Q3 2024 Adjusted EBITDA(1) of $146 million increased 9.0%, compared to Q3 2023Q3 2024 Adjusted EPS(1) of $0.17 increased $0.01 per diluted share, compared to Q3 2023Reaffirming 2024 Net Revenue and Adjusted EBITDA outlook ranges CLEVELAND, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry,

CLEVELAND, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the third-quarter ended September 30, 2024 before the market opens on Tuesday, November 5, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from other locations.

Q2 2024 net revenues of $277 million increased 8%, compared to Q2 2023Q2 2024 net income of $9 million or $0.03 per diluted share, compared to net income of $24 million or $0.08 per diluted share in Q2 2023Q2 2024 Adjusted EBITDA(1) of $137 million increased 7%, compared to Q2 2023Q2 2024 Adjusted EPS(1) of $0.19 declined $0.01 per diluted share, compared to Adjusted EPS of $0.20 in Q2 2023Successfully refinanced debt structure, extending debt maturities to 2031Reaffirming 2024 outlook CLEVELAND, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab test

CLEVELAND, July 22, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the second-quarter ended June 30, 2024 before the market opens on Monday, August 5, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from other locations. A live

Q1 2024 net revenues increased 12.5% to $248 million, compared to Q1 2023Q1 2024 net income of $6 million or $0.02 per diluted share, compared to net income of $3 million or $0.01 per diluted share in Q1 2023Q1 2024 Adjusted EBITDA(1) increased 13.7% to $112 million, compared to Q1 2023Q1 2024 Adjusted EPS(1) of $0.13 compared to Adjusted EPS of $0.13 in Q1 2023Company reaffirms 2024 outlook CLEVELAND, May 02, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the

CLEVELAND, April 11, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the first-quarter ended March 31, 2024 before the market opens on Thursday, May 2, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from other locations. A live

2023 net revenues increased 4.5% to $1.05 billion, compared to 20222023 net income of $51 million or $0.18 per diluted share2023 Adjusted EBITDA(1) increased 4.3% to $528 million2023 Adjusted EPS(1) decreased $0.15 to $0.81 per diluted shareFull-year 2024 outlook of 4.0% - 6.0% growth for Net Revenues and Adjusted EBITDA CLEVELAND, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the fourth-quarter and full-year 2023 and its initial 2024 outlook. For th

CLEVELAND, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2023 before the market opens on Tuesday, February 27, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from o

Q3 2023 net revenues of $263 million increased 6%, compared to Q3 2022Q3 2023 net loss of $14 million or $0.05 per diluted share, compared to net income of $25 million or $0.09 per diluted share in Q3 2022 Q3 2023 Adjusted EBITDA of $134 million increased 7%, compared to Q3 2022Q3 2023 Adjusted EPS of $0.21 decreased $0.02 per diluted share, compared to Q3 2022 driven by higher interest expenseCompany reaffirms 2023 outlook, anticipates results at the lower end of the range CLEVELAND, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advi

CLEVELAND, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the third-quarter ended September 30, 2023 before the market opens on Wednesday, November 1, 2023. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412- 317-0709 if dialing-in from oth

Q2 2023 net revenues of $255 million decreased 4%, compared to Q2 2022, primarily driven by expected Nordion Cobalt-60 harvest schedule timingQ2 2023 net income of $24 million or $0.08 per diluted share, compared to net income of $30 million or $0.11 per diluted share in Q2 2022Q2 2023 Adjusted EBITDA of $128 million decreased 6%, compared to Q2 2022, driven by expected Nordion Cobalt-60 harvest schedule timingQ2 2023 Adjusted EPS of $0.21 decreased $0.06 per diluted share, compared to Q2 2022 Total debt of $2.3 billion and net leverage ratio of 4.2x as of June 30, 2023Adjusting full-year 2023 net revenue outlook to $1.035 billion to $1.055 billion and Adjusted EBITDA to $520 million to $535

CLEVELAND, July 18, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the second-quarter ended June 30, 2023 before the market opens on Thursday, August 3, 2023. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-877-270-2148 if dialing-in from the United States, or 1-412-902-6510 if dialing-in from other locations. For

Q1 2023 net revenues of $221 million decreased 7%, compared to Q1 2022, primarily driven by Nordion Cobalt-60 harvest schedule timing, as expectedQ1 2023 net income of $3 million or $0.01 per diluted share, compared to net income of $31 million or $0.11 per diluted share in Q1 2022Q1 2023 Adjusted EBITDA of $98 million decreased 15%, compared to Q1 2022, driven by Nordion Cobalt-60 harvest schedule timing, as expectedQ1 2023 Adjusted EPS of $0.13 decreased by $0.09 per diluted share, compared to Q1 2022Total debt of $2.3 billion and net leverage ratio of 3.4x as of March 31, 2023Company reaffirms 2023 outlook CLEVELAND, May 03, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Hea

CLEVELAND, April 18, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the first-quarter ended March 31, 2023 before the market opens on Wednesday, May 3, 2023. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-866-777-2509 if dialing-in from the United States, or 1-412-317-5413 if dialing-in from other locations. For d

Q4 2022 net revenues increased 4% to $252 million, compared to Q4 2021Q4 2022 net loss of $320 million or $1.14 per diluted share, which includes a $408 million legal reserve recorded in Q4 2022, compared to net income of $36 million or $0.13 per diluted share in Q4 2021Q4 2022 Adjusted EBITDA increased 4% to $130 million, compared to Q4 2021Q4 2022 Adjusted EPS of $0.25 improved by $0.02 per diluted share, compared to Q4 2021Closed on $500 million aggregate principal amount Term Loan B in FebruaryFull-year 2023 outlook Net Revenues and Adjusted EBITDA growth of 5% to 9% CLEVELAND, Feb. 28, 2023 (GLOBE NEWSWIRE) --  Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC),

CLEVELAND, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2022 before the market opens on Tuesday, February 28, 2023. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-866-777-2509 if dialing-in from the United States, or 1-412-317-5413 if dialing-in from o

Q3 2022 net revenues of $249 million increased 10%, compared to Q3 2021Q3 2022 net income of $25 million or $0.09 per diluted share, compared to net income of $27 million or $0.10 per diluted share in Q3 2021Q3 2022 Adjusted EBITDA of $125 million increased 7%, compared to Q3 2021Q3 2022 Adjusted EPS of $0.23 improved $0.02 compared to Q3 2021Adjusting full-year 2022 net revenue growth outlook to 7% - 8% and Adjusted EBITDA growth to 4% - 6%The Company announced today that Alex Dimitrief joined as General Counsel effective November 1st CLEVELAND, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-

CLEVELAND, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the third quarter ended September 30, 2022 before market open on Wednesday, November 2, 2022. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. Participants may access the conference call live via webcast on the ‘Presentations & Events' page of Sotera Health's website at Presentation & Events |

Q2 2022 net revenues of $267 million increased 6%, compared to Q2 2021Q2 2022 net income of $30 million or $0.11 per diluted share, compared to net income of $43 million or $0.15 per diluted share in Q2 2021Q2 2022 Adjusted EBITDA of $136 million increased 1%, compared to Q2 2021Q2 2022 Adjusted EPS of $0.27 increased $0.01, compared to Q2 2021 Narrowing full-year 2022 net revenues and Adjusted EBITDA outlook in the range of $1.0 to $1.022 billion and $515 to $525 million, respectively CLEVELAND, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab test

CLEVELAND, July 20, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the second quarter ended June 30, 2022, before the Nasdaq market open on Thursday, August 4, 2022. Following the release, management will hold a conference call at 9:00a.m. Eastern Time to discuss the Company's operating highlights and financial results. Participants may access the conference call live via webcast on the ‘Presentations & Events' page of Sotera Health's website at https://investors.sote

Q1 2022 net revenues of $237 million increased 12%, compared to Q1 2021Q1 2022 net income of $31 million or $0.11 per diluted share, compared to net income of $11 million or $0.04 per diluted share in Q1 2021Q1 2022 Adjusted EBITDA of $115 million increased 10%, compared to Q1 2021Q1 2022 Adjusted EPS of $0.22 improved by $0.04 per diluted share, compared to Q1 2021March 31, 2022 total debt of $1.79 billion and net leverage ratio improved to 3.4xCompany reaffirms 2022 outlook CLEVELAND, May 05, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and adv

CLEVELAND, April 21, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the first quarter ended March 31, 2022 before market open on Thursday, May 5, 2022. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-866-777-2509 if dialing-in from the United States, or 1-412-317-5413 if dialing-in from other locations. For direct

CLEVELAND, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth quarter and full year ended December 31, 2021 before market open on Tuesday, March 1, 2022. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-833-303-1211 if dialing-in from the United States or Canada, or 1-918-922-6527 if dialing-in from

Q3 2021 net revenues of $226 million increased 13%, compared to Q3 2020Q3 2021 net income of $27 million or $0.10 per diluted share, compared to net income of $0.01 million or $0.00 per diluted share in Q3 2020Q3 2021 Adjusted EBITDA of $117 million increased 16%, compared to Q3 2020Q3 2021 Adjusted EPS of $0.21 improved $0.12 compared to Q3 2020September 30, 2021 total debt of $1.8 billion and total net debt of $1.7 billion; net leverage ratio improved to 3.6xNarrowing full-year 2021 revenue growth outlook to 12% - 14% and full-year 2021 Adjusted EBITDA growth to 13% - 14%Full redemption of $100 million Senior Secured First-Lien Notes CLEVELAND, Nov. 10, 2021 (GLOBE NEWSW

CLEVELAND, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the third quarter and nine months ended September 30, 2021 before market open on Wednesday, November 10, 2021. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-833-303-1211 if dialing-in from the United States or Canada, or 1-918-922-6527 if dial

Q2 2021 net revenues of $252 million increased approximately 18%, compared to Q2 2020Q2 2021 net income of $43 million or $0.15 per diluted share, compared to net income of $7 million or $0.03 per diluted share in Q2 2020Q2 2021 Adjusted EBITDA of $135 million increased approximately 18%, compared to Q2 2020Q2 2021 Adjusted EPS of $0.26 improved $0.12 compared to Q2 2020 Adjusted EPS of $0.14June 30, 2021 total debt of $1.9 billion and net debt of $1.7 billion; net leverage ratio improved to 3.8xIncreasing full-year 2021 revenue growth outlook from 9%-12% to 12%-15% and increasing full-year 2021 Adjusted EBITDA growth outlook from 11%-16% to 13%-17%Full redemption of $100M Senior Secured Fir